| Drug Name |
Rimonabant hydrochloride |
| Drug ID |
BADD_D01947 |
| Description |
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression. |
| Indications and Usage |
For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia. |
| Marketing Status |
approved; investigational |
| ATC Code |
A08AX01 |
| DrugBank ID |
DB06155
|
| KEGG ID |
D05731
|
| MeSH ID |
D000077285
|
| PubChem ID |
104849
|
| TTD Drug ID |
D0O3OS
|
| NDC Product Code |
Not Available |
| UNII |
HL0V2LQZ09
|
| Synonyms |
Rimonabant | SR141716 | SR 141716 | Rimonabant Hydrochloride | N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride | Zimulti | SR 141716A | SR-141716A | SR141716A | Acomplia |
